Ignite Creation Date:
2024-05-05 @ 4:40 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00280865
Status:
COMPLETED
Last Update Posted:
2006-07-31
First Post:
2006-01-20
Brief Title:
GLAD Dose-Finding Efficacy and Safety of AZ 242 Tesaglitazar in Subjects With Type 2 Diabetes
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
Dose-Finding Efficacy and Safety of AZ 242 Tesaglitazar in Subjects With Type 2 Diabetes
Status:
COMPLETED
Status Verified Date:
2006-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a 12-week randomized double-blind multi-center active-controlled open-label pioglitazone and placebo-controlled study of tesaglitazar 01 05 1 2 and 3 mg in patients with type 2 diabetes not adequately controlled on diet and lifestyle advice alone during the run-in period The study comprises a 2-week enrollment period 4 week placebo single blind run in period followed by a 12-week double blind treatment period and a 3-week follow-up period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| GLAD | None | None | None |